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Abstract
Background: Celiac disease (CD) may affect healthcare use in children and young adults. Socio-economic factors
may act as a confounder or effect modifier. We assessed such hypotheses in a population-based birth cohort of
young celiac subjects and references matched by maternal education.
Methods: The cohort included all newborns recorded in the Medical Birth Register of Friuli-Venezia Giulia Region
(Italy) between 1989 and 2011. CD incident cases were identified through pathology reports, hospital discharges
and copayment exemptions and matched with up to five references by sex, year of birth and maternal education.
Cox regression models were used to estimate Hazard Ratios (HRs) for major causes of inpatient diagnosis and drug
prescription occurring after diagnosis in CD patients compared to references, stratifying by time of first event and
maternal education.
Results: We identified 1294 CD cases and 5681 references. CD cases had a higher risk of hospital admission for
any cause (HR: 2.34; 95 % CI 2.08-2.63) and for all major ICD9-CM categories except obstetric complications, skin
and musculoskeletal diseases, and injuries and poisoning. Prescription of all major ATC drug categories, except
dermatologicals and genito-urinary medications, was significantly increased in CD subjects. For most outcomes, HRs
were highest in the first year after CD diagnosis but remained significant after five or more years. HRs were similar
across different categories of maternal education.
Conclusions: Diagnosed CD subjects had a higher risk of hospitalization and medication use compared to the
general population, even five or more years after diagnosis, with no effect modification of maternal education.
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Background
Celiac disease (CD) is an immune-mediated small intes-
tinal enteropathy triggered by gluten affecting approxi-
mately 0.5-1 % of the European population and frequently
diagnosed during childhood [1].
Originally considered a rare malabsorption syndrome
of childhood, CD is now recognized as a systemic dis-
order potentially affecting many organ systems beyond
the gastrointestinal tract [2]. The clinical picture is vari-
able and several complications and comorbidities can
occur, including consequences of malnutrition (e.g., low
bone mineral density, anemia), infections, neurological
and autoimmune diseases (e.g. type I diabetes, thyroid
disorders), [2, 3] and cancers such as lymphoma [4]. The
only available treatment for CD is a life-long gluten-free
diet. This dietary regimen is effective in controlling
symptoms, however it is burdensome for the patient and
his/her family and cannot prevent many complications
and comorbidities of CD [2]. Moreover, children with
CD, even if adherent to the gluten-free diet, often suffer
from functional gastrointestinal disorders [5] and psy-
chological disturbances [6] that may lead to impaired
quality of life [7] and greater healthcare needs.
Few studies have investigated and reported an in-
creased use of healthcare services and drugs and associ-
ated costs in adults with CD compared to the general
population; [8–11] specific data regarding children and
adolescents with CD are scarce. Furthermore, only one
study [11] has so far assessed the long-term persistence
of increased healthcare use after CD diagnosis.
Healthcare utilization pattern is affected by educational
and socio-economic factors, which may reflect socio-
economic differences regarding both morbidity and access
to healthcare services. Currently, social determinants are
emphasised as a major source of health inequalities within
developed countries [12]. As far as we know, the impact
of socio-economic status on healthcare utilization associ-
ated with CD has never been investigated.
Using a population-based birth cohort of subjects born
between 1989 and 2011 and followed-up until the end of
2012, we examined the risk of first hospitalization and
drug consumption at different time intervals from diag-
nosis in CD children, adolescents and young adults com-
pared to reference individuals matched on age, gender
and maternal education level. This study had three ob-
jectives: i) to assess whether children and adolescents
with CD use more healthcare resources after diagnosis
compared to subjects without CD of similar age, sex,
and maternal education; ii) to assess whether the
possible increased healthcare use is limited to the short
period after CD diagnosis or persists long-term; iii) to
assess whether the risk of healthcare use in CD subjects
compared to unaffected subjects is modified by maternal
education.
Methods
Setting and study population
We used a matched cohort design. The underlying study
population consisted of 213 635 subjects (excluding abor-
tions, stillbirths, and neonatal deaths within 30 days of
birth) born in Friuli-Venezia Giulia (FVG) Region in Italy
in the period 1989-2011 identified using the regional
Medical Birth Register that contains socio-demographic
data on the parents, details of the pregnancy, labour, and
delivery, and the newborn at birth.
Italy has a tax-based National Health Service, which
provides universal coverage to all Italian and European
Union citizens resident in the country regardless of
income, and it is organized at a regional level. FVG
Region is covered by a regional integrated healthcare
system developed in the 1980s with the goal of automat-
ically collecting and pooling data on healthcare funded
by the National Health Service using a unique regional
identification code that has been described in detail pre-
viously [13].
The following Regional health data were used in this
study (up to 2012): mortality records; pathology reports
from all the pathology departments in the FVG Region,
coded in the Systematized Nomenclature of Medicine
(SnoMed); hospital discharge records collected during
episodes of inpatient care occurring within the FVG
Region or in Italy outside the Region with up to six
diagnostic codes in the International Classification of
Diseases ninth revision Clinical Modification (ICD9-CM);
exemption from healthcare copayment coded in a national
coding system; drug prescription records coded in the
Anatomical Therapeutic Chemical (ATC) Classification
System (available from 1995).
Ethics, consent and permissions
The study was approved by the Institutional Review
Board of the University of Padua (Italy). Patients’ data
were completely anonymized and de-identified prior to
analysis. Therefore, no informed consent and no Ethics
Committee approval were required.
CD definition
We defined CD as having at least one of the following
[13]: a pathology report of villous atrophy (SnoMed
codes D6218, D6318, M58, M58005, M58006, and
M58007); a hospital discharge record with an ICD9-CM
code 5790 in any diagnosis; an exemption from health-
care copayment with code I0060 according to the Italian
national coding system. In Italy, all patients with CD can
obtain clinical tests and gluten-free food free of charge
from the National Health Service, provided they have a
CD diagnosis certified by a specialist on the basis of a
biopsy report. CD onset was defined as the earliest date
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identifiable in the three sources of information (pathology,
hospital and copayment exemption).
Follow-up
We retrieved data on hospital discharges by cause of dis-
ease according to ICD9-CM classification (17 group of
causes listed in Table 1) considering the main diagnosis
and drug prescriptions according to first level of ATC
Classification after date of diagnosis (index date in refer-
ence individuals).
Data analysis
For each case with a CD diagnosis up to five reference
individuals were selected from subjects in the Medical
Birth Register alive on the date of CD diagnosis (index
date), matched on gender, year of birth and maternal
education levels (up to middle school; secondary school;
university level). Matching was implemented to control
for confounding and improve statistical efficiency and to
be able to attribute the beginning of follow-up (index
date) that corresponds to CD diagnosis to reference indi-
viduals. Follow-up started at 30 days after the index date
(to exclude hospitalizations and prescriptions concomi-
tant to CD diagnosis) until the earliest of: end of the
study (December 31, 2012), death, migration out of the
area, or first hospitalization for each group of causes/
first drug prescription for each ATC level. Concerning
drug prescription outcomes, analyses were restricted to
subjects with index date ≥1995 (because drug prescrip-
tion data are available from that year). Cox regression
models were used to estimate the Hazard Ratios (HRs)
and 95 % confidence intervals (CI) for each of the
healthcare use outcome in patients with CD compared
to reference individuals within the same stratum. The
assumption of proportional hazards was investigated by
studying graphs over the log cumulative hazards func-
tion and the Shoenfeld residuals, and verified by a global
test of rho. Analyses were also stratified by time of first
hospital admission/drug prescription, looking at out-
comes occurred between 30-365 days and >365 days
after the index date. For the latter analyses only subjects
with at least one year of follow-up (alive and resident in
the area one year after the index date and without any
hospitalization/drug prescription for each ICD9-CM/
ATC category within one year from the index date) were
considered. In order to assess the possible long-term
effect on healthcare use in CD individuals compared to
references, we examined the risk of hospitalization and
drug consumption five or more years after diagnosis. For
this analysis follow-up started five years after the index
Table 1 Risks of first hospital admission according to ICD9-CM classification after date of diagnosis in CD subjects compared to
matched referencesa
ICD codes Disease category REFERENCES (n = 5681) CD (n = 1294) HR (95 % CI)
n py n py
001–V89 Any 1245 33072 499 5915 2.34 (2.08–2.63)
001–139 Infectious and parasitic diseases 73 40900 44 9396 2.79 (1.89–4.12)
140–239 Neoplasms 56 41220 27 9686 1.89 (1.16–3.08)
240–279 Endocrine. metabolic. immunity dis. 96 40936 69 9328 3.19 (2.32–4.40)
280–289 Dis. of the blood and blood–forming organs 23 41334 25 9614 4.47 (2.49–8.01)
290–319 Mental disorders 60 41203 35 9618 2.52 (1.64–3.87)
320–389 Dis. of the nervous system and sense organs 114 40681 56 9414 2.14 (1.53–2.98)
390–459 Dis. of the circulatory system 29 41405 16 9766 2.77 (1.49–5.18)
460–519 Dis. of the respiratory system 347 38348 121 8763 1.59 (1.28–1.98)
520–579 Dis. of the digestive system 220 40228 232 7846 5.59 (4.57–6.83)
580–629 Dis. of the genito–urinary system 94 40861 42 9533 1.95 (1.32–2.86)
630–679 Complications of pregnancy and puerperium 46 41394 15 9807 1.48 (0.82–2.67)
680–709 Dis. of skin and subcutaneous tissue 55 41215 16 9722 1.22 (0.68–2.17)
710–739 Dis. of the muscoloskeletal tissue 104 41056 27 9716 0.88 (0.55–1.44)
740–779 Congenital anomalies/Perinatal conditions 90 40902 44 9482 2.18 (1.50–3.17)
780–799 Ill-defined conditions 83 40898 55 9413 2.94 (2.06–4.19)
800–999 Injuries and poisoning 167 41491 57 9840 1.35 (0.98–1.86)
V01–V89 Factors influencing health status 58 41092 41 9468 2.94 (1.94–4.47)
Py person-years, CD celiac disease, HR Hazard Ratio, CI confidence interval, Dis. Disease
Figures in bold are statistically significant results (p-value <0.05)
aMatched by year of birth, gender and maternal education
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date and only subjects alive and resident in the area at
this time were included. In this analysis, we included
subjects with hospitalization/drug prescription within
five years from the index date.
In order to evaluate a possible modifying effect of so-
cioeconomic status, analyses were subsequently stratified
by maternal education levels.
Results
We identified 1294 subjects with CD and 5681 reference
individuals. Biopsy confirmation was available for 920
(71 %) CD individuals; 179 (14 %) were instead identified
by hospital discharges and copayment records, 112 (9 %)
only by hospital discharge records and 83 (6 %) only by
copayment records. Mean age at diagnosis (age at index
date for references) was 7.2 ± 5.3 years (min 0, max
23.8 years). Analyses of drug prescriptions were restricted
to 1215 CD subjects diagnosed after 1995 and 5366
matched references. 1166 CD cases (5100 references) were
alive and resident in the Region one year after the index
date and 777 (3316 references) 5 years after.
CD subjects were at increased risk of hospital admis-
sion for any cause (HR: 2.34; 95 % CI: 2.08-2.63) and for
all major groups of causes according to ICD9-CM classi-
fication, except for complications of pregnancy and
puerperium, diseases of skin and subcutaneous tissue,
diseases of the musculoskeletal tissue, and injuries and
poisoning (Table 1). The risk of drug prescription was
also significantly increased in CD cases for all ATC cat-
egories except dermatologicals (ATC =D) and genito-
urinary medications and sex hormones (ATC =G)
(Table 2).
The risk of any hospital admission in CD subjects
compared to references was higher during the first year
after diagnosis but remained statistically significant also
after the first year of follow-up (Table 3). Examining sin-
gle major groups of causes, the chronological pattern
was heterogeneous (Table 3): for endocrine/metabolic/
immune disorders and digestive disorders HRs were
higher during the first year and declined afterwards; a
similar pattern was seen, although less evident, for infec-
tious, respiratory, and congenital disorders, for ill-
defined conditions and factors influencing health status.
On the contrary, hospitalization for nervous/sensory dis-
orders and genito-urinary disorders had similar HRs
within one year from diagnosis and after one year. Fi-
nally, concerning blood, mental and circulatory disor-
ders, the low number of events occurring during the
first year did not allow to estimate hazard ratios. Five
years after diagnosis, CD subjects still had a higher risk
of being admitted to the hospital for any cause (HR:
2.03; 95 % CI: 1.71-2.41) and for infectious (HR: 2.45;
95 % CI: 1.24-4.85), endocrine/metabolic/immune (HR:
3.13; 95 % CI: 1.94-5.06), mental (HR: 1.99; 95 % CI:
1.04-3.81), nervous/sensory (HR: 2.76; 95 % CI: 1.62-
4.72), circulatory (HR: 2.39; 95 % CI: 1.14-5.00), digestive
(HR: 2.90; 95 % CI: 2.09-4.02), and congenital disorders
(HR: 2.93; 95 % CI: 1.64-5.21), as well as for ill-defined
conditions (HR: 2.62; 95 % CI: 1.50-4.61) and factors in-
fluencing health status (HR: 4.87; 95 % CI: 2.32-10.23)
(Additional file 1: Table S1).
The risk of drug prescription was higher in the first
year after diagnosis for all ATC groups, except for sys-
temic anti-infectives (ATC = J) and respiratory system
(ATC = R) medications, which showed a stable risk over
time (Table 4). Risk estimates for cardiovascular drugs
(ATC = C), genito-urinary drugs and sex hormones
(ATC =G), nervous system drugs (ATC =N), and sen-
sory organs medications (ATC = S) were significantly in-
creased only in the first year of follow-up. Five years
after diagnosis, CD subjects still had a higher risk of be-
ing prescribed most drug categories compared to their
references (Additional file 2: Table S2).
Among CD cases, 160 (12.4 %) were born to graduated
mothers, 648 (50.1 %) to mothers with secondary school
education and 471 (36.4 %) to less educated mothers (up
to middle school) (15 cases had missing information on
maternal education); by study design, references showed
similar distributions, because each CD case was matched
to references with the same maternal education.
In the analysis stratified by maternal education level,
we found no clear modifying effect of maternal
education (Additional file 3: Table S3, Additional file 4:
Table S4). The risks of being hospitalized for any cause
among CD subjects compared to their references born
to mothers with similar maternal education were: HR
2.64 (95 % CI 1.79-3.89) for university level, HR 2.33
(95 % CI 1.97-2.76) for secondary school education and
HR 2.30 (95 % CI 1.92-2.75) for primary/middle school
education. Neither were there any differences in HRs for
specific groups of causes according to maternal education
although the low number of subjects with graduated
mothers did not allow precise or computable estimates
in that group (Additional file 3: Table S3). Similar
risks were also seen for the majority of drug prescription
categories in the groups of subjects stratified by maternal
education (Additional file 4: Table S4).
Discussion
In this large population-based birth cohort, we followed-
up 1294 children and adolescents with CD and 5,681
peers without CD, matched by socio-demographic char-
acteristics, for hospitalization and drug prescription after
CD diagnosis. Both hospitalization and drug consump-
tion were increased in CD cases in most disease cate-
gories and a wide range of drug classes.
A small number of previous studies have reported a
greater use of medical services and drugs in CD patients
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Table 3 Risks of first hospital admission according to ICD9–CM classification after date of diagnosis in CD subjects compared to
matched references, stratified by first outcome occurrence (30–365 days after the index date/>365 days after the index date)a
First outcome occurrence 30–365 days >1 year after index dateb
ICD codes REFERENCES CD HR (95 % CI) REFERENCES CD HR (95 % CI)
n py n py n py n py
001–V89 281 5260 243 1095 4.28 (3.56–5.13) 964 27812 256 4820 1.58 (1.36–1.85)
001–139 18 5380 17 1221 4.38 (2.25–8.55) 55 35520 27 8176 2.23 (1.37–3.63)
140–239 8 5384 6 1226 2.88 (0.94–8.85) 6 35836 21 8459 1.72 (1.00–2.98)
240–279 12 5383 24 1216 8.37 (4.12–16.99) 84 35553 45 8112 2.42 (1.66–3.52)
280–289 7 5426 13 1309 - - 16 35947 12 8392 2.70 (1.21–6.04)
290–319 12 5476 9 1272 - - 48 35819 26 8394 2.26 (1.37–3.72)
320–389 32 5375 13 1224 1.83 (0.94–3.56) 82 35306 43 8190 2.26 (1.54–3.32)
390–459 2 5388 0 1229 - - 27 36017 16 8537 2.99 (1.59–5.64)
460–519 66 5356 38 1213 2.62 (1.74–3.95) 281 32991 83 7550 1.34 (1.03–1.73)
520–579 30 5375 123 1156 18.96 (12.52–28.70) 190 34853 109 6690 3.07 (2.38–3.97)
580–629 23 5378 11 1226 1.92 (0.88–4.19) 71 35483 31 8307 1.95 (1.25–3.05)
630–679 1 5388 0 1229 - - 45 36006 15 8578 1.57 (0.87–2.82)
680–709 6 5385 2 1228 0.81 (0.10–6.70) 49 35830 14 8493 1.27 (0.69–2.32)
710–739 12 5384 7 1226 2.32 (0.87–6.21) 92 35672 20 8490 0.70 (0.39–1.23)
740–779 21 5381 16 1220 3.39 (1.74–6.59) 69 35521 28 8262 1.80 (1.14–2.85)
780–799 16 5381 18 1220 5.43 (2.76–10.66) 67 35517 37 8193 2.33 (1.52–3.56)
800–999 1 5389 1 1229 5.00 (0.31–79.95) 166 36102 56 8611 1.33 (0.97–1.83)
V01–V89 15 5379 15 1223 4.18 (2.00–8.74) 43 35713 26 8245 2.50 (1.50–4.17)
Py person–years, CD celiac disease, HR Hazard Ratio, CI confidence interval, Figures in bold are statistically significant results (p-value <0.05)
aMatched by year of birth, gender and maternal education; bexcluding subjects with less than one year of follow-up for each outcome
Table 2 Risks of first drug prescription according to first level of Anatomical Therapeutic Chemical (ATC) Classification after date of
diagnosis in CD subjects compared to matched referencesa
ATC codes Drug category REFERENCES (n = 5366) CD (n = 1215) HR (95 % CI)
n py n py
A Alimentary tract and metabolism 537 38094 298 8054 2.55 (2.19–2.97)
B Blood and blood forming organs 258 40354 193 8846 3.69 (3.02–4.50)
C Cardiovascular system 102 40676 43 9511 1.77 (1.22–2.57)
D Dermatologicals 180 40060 55 9381 1.22 (0.88–1.69)
G Genito–urinary system and sex hormones 126 40749 38 9629 1.22 (0.83–1.79)
H Systemic hormonal preparations. excluding sex hormones and insulins 778 37614 316 8082 2.06 (1.79–2.37)
J Antiinfectives for systemic use 3660 17612 885 3680 1.27 (1.17–1.39)
L Antineoplastic and immunomodulating agents 19 41350 25 9697 5.24 (2.82–9.73)
M Musculo–skeletal system 170 40674 73 9436 1.93 (1.44–2.59)
N Nervous system 156 40703 56 9533 1.53 (1.12–2.11)
P Antiparasitic products. insecticides and repellents 216 40259 90 9271 2.01 (1.56–2.60)
R Respiratory system 2059 27958 560 6004 1.33 (1.20–1.48)
S Sensory organs 147 39939 51 9252 1.42 (1.02–1.99)
Py: person-years; CD: celiac disease; HR: Hazard Ratio; CI: confidence interval
Figures in bold are statistically significant results (p-value <0.05)
aMatched by year of birth, gender and maternal education; analysis restricted to subjects with index date ≥1995 (because drug prescription data are available
from that year)
Canova et al. BMC Gastroenterology  (2016) 16:1 Page 5 of 9
compared to controls after diagnosis, [9–11] but only
one included children and adolescents and provided a
long follow-up [11]. To our knowledge, this is the first
study on the long-term healthcare impact of paediatric
CD conducted in Southern Europe. Healthcare use is
influenced by culture and type of healthcare system,
therefore it is worthwhile to conduct similar studies in
different settings. Overall the results of the present study
are consistent with current knowledge that childhood
CD is associated with multi-organic complications and
comorbidities and also with non-specific health com-
plaints [2, 3].
For most disease and drug categories (in particular
endocrine/metabolic/immune and digestive disorders
and antineoplastic/immunomodulating agents), the risk
of hospitalization or prescription was highest during the
first year of follow-up, indicating that CD-related health
problems are likelier to occur (or become recorded)
shortly after diagnosis, when clinical surveillance is
greatest and dietary treatment may have not yet dis-
played its effects. However, our findings suggest that
CD-related health problems can develop also later, since
for most conditions the risk of a first event after diagno-
sis was increased in CD subjects compared to reference
individuals also after the first year of follow-up. To as-
sess whether the increased healthcare use in CD per-
sisted long-term, we also examined hospital admissions
and drug prescriptions occurring five or more years after
diagnosis; subjects who had hospital admissions or drug
prescription within five years were included in this ana-
lysis. We found that even beyond five years of follow-up,
the risk of hospitalization and drug prescription was
greater in CD cases compared to reference individuals.
Such results are consistent with a previous study con-
ducted in the United Kingdom showing that healthcare
costs in patients with CD have a peak around time of
diagnosis and decline thereafter, but remain higher than
in controls for up to 10 years [11]. Unlike the above-
mentioned study, we did not focused on costs but rather
on the risk of events.
Different factors may explain why diagnosed CD chil-
dren and adolescents used more healthcare resources
than their references even five years after diagnosis. First
of all, as in any chronic disorder, the frequent contact
with the healthcare system can increase the chance of
being diagnosed and subsequently treated for other con-
ditions. In our opinion, however, surveillance bias alone
cannot explain the differences we observed. Secondly,
CD has been associated with non-specific health com-
plaints such as functional gastrointestinal disorders and
depressive and anxiety symptoms that can persist over time
despite appropriate treatment [5, 6]. Consistently, when we
examined main diagnoses and drug categories in detail, we
found that anxiety and somatoform disorders (ICD9-CM
300), personality disorders (ICD9-CM 301), eating, sleep
and psychogenic pain disorders (ICD9-CM 307), ill-
defined symptoms concerning nutrition and abdomen
(ICD9-CM 783 and 789), prescriptions of antacids (ATC
Table 4 Risks of first drug prescription according to first level of Anatomical Therapeutic Chemical (ATC) Classification after date of
diagnosis in CD subjects compared to matched references, stratified by first outcome occurrence (30–365 days after the index
date/>365 days after the index date)a
First outcome occurrence 30–365 days >1 year after index dateb
ATC codesb REFERENCES CD HR (95 % CI) REFERENCES CD HR (95 % CI)
n py n py n py n py
A 131 5320 140 1129 4.70 (3.66–6.04) 406 32774 158 6926 1.78 (1.45–2.17)
B 48 5543 91 1534 6.35 (2.93–13.75) 210 34991 102 7669 2.36 (1.83–3.04)
C 18 5380 14 1222 3.53 (1.71–7.29) 84 35296 29 8289 1.42 (0.91–2.21)
D 43 5367 17 1220 1.45 (0.79–2.64) 137 34694 38 8162 1.14 (0.77–1.68)
G 22 5375 14 1221 2.38 (1.16–4.88) 104 35374 24 8408 0.97 (0.61–1.54)
H 209 5286 133 1157 3.07 (2.45–3.85) 569 32328 183 6925 1.65 (1.38–1.97)
J 1986 4300 524 941 1.27 (1.15–1.41) 1674 13312 361 2739 1.28 (1.10–1.49)
L 4 5386 12 1221 12.46 (3.94–39.42) 15 35964 13 8476 3.33 (1.52–7.29)
M 15 5383 14 1221 3.64 (1.66–7.97) 155 35291 59 8214 1.75 (1.27–2.41)
N 31 5368 16 1217 2.22 (1.20–4.12) 125 35335 40 8316 1.35 (0.93–1.97)
P 44 5368 30 1211 3.05 (1.88–4.94) 172 34891 60 8060 1.73 (1.27–2.35)
R 808 4969 248 1097 1.42 (1.23–1.65) 1251 22989 312 4907 1.26 (1.09–1.45)
S 43 5368 25 1217 2.29 (1.37–3.83) 104 34572 26 8035 1.03 (0.65–1.64)
Py: person–years; CD: celiac disease; HR: Hazard Ratio; CI: confidence interval
Figures in bold are statistically significant results (p-value <0.05)
aMatched by year of birth, gender and maternal education; analysis restricted to subjects with index date ≥1995 (because drug prescription data are available
from that year); bexcluding subjects with less than one year of follow-up for each outcome
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A02), psycholeptics (ATC N05), and psychoanaleptics
(ATC N06) were all more common among individuals with
CD. Young CD patients may also be exposed to a persist-
ent risk of developing complications of nutritional defi-
ciencies due to incomplete remission of gut mucosal
abnormalities or to dietary restrictions [14]. This is
suggested by our finding that CD subjects had a higher
proportion of iron-deficiency anemia (ICD9-CM 280),
thrombocytopenia (ICD9-CM 287), leukocytopenia (ICD9-
CM 288), and prescription of anti-anemic preparations
(ATC B03). Infectious diseases, particularly those provoked
by encapsulated bacteria, may also complicate the clinical
course of CD in the long term, [15] as a result of hypos-
plenism [16] and perhaps of altered intestinal permeability
and nutritional deficiencies. We also observed a greater
frequency of hospital admissions for otitis media (ICD9-
CM 381), pneumonia (ICD9-CM 481, 482, 485, 486), and
urinary infections (ICD9-CM 590, 599) in CD, as well as a
higher consumption of systemic anti-infectives (ATC J). Fi-
nally, a greater occurrence of several diseases, mainly but
not exclusively of autoimmune origin, has been described
in patients with CD. Although our study was not designed
to estimate the risk of specific associated conditions, we
think that some of the reported risks could be partially ex-
plained by underlying comorbidities. For instance, the
greater proportion of admissions for diabetes (ICD9-CM
250) and prescription of antidiabetic agents (ATC A10)
and thyroid drugs (ATC H03) could reflect the acknowl-
edged associations between CD and type I diabetes melli-
tus and autoimmune thyroid disorders [17]. Similarly, the
well-known comorbidity between CD and chromosomal
anomalies, such as Down [18] and Turner syndrome, [3]
may in part explain a higher prevalence of congenital mal-
formations in CD subjects [19]. Several neurologic and
psychiatric conditions, such as epilepsy (ICD9-CM 345)
[20] and autism (ICD9-CM 299), [3, 21] have been linked
to CD although with inconclusive results, and may explain
our finding of a higher risk of hospital admission for
neurologic and mental disorders and of prescription of an-
tiepileptic drugs (ATC N03) in CD cases. Concerning di-
gestive disorders, most of the increased risk in CD subjects
is likely due to CD itself, especially in the first year of
follow-up, since intestinal malabsorption (ICD9-CM 579)
was not excluded from the analysis of hospitalization
outcomes. Our CD cases also had a high frequency of
hospitalizations for Crohn’s disease (ICD9-CM 555) and
ulcerative colitis (ICD9-CM 556), both of which have been
potentially linked to CD although earlier research has
shown conflicting results [22–25].
Although CD is a chronic illness, many of its symp-
toms and effects can be reversed or controlled with a
gluten-free diet [2]. Therefore, one might suppose that
with a well-conducted gluten-free diet and an appro-
priate follow-up, the long-term outcome of CD paediatric
patients would be similar to the general population ones.
Our data showed that this is not the case, at least not in
FVG Region. This issue deserves further investigation to
confirm our findings and to assess whether the unfavor-
able long-term outcome of paediatric CD can be attrib-
uted only to complications and comorbidities that are not
prevented by the gluten-free diet or also to an inadequate
management of CD.
Socioeconomic factors in early childhood have a well-
known impact on several health outcomes in adulthood,
although evidence regarding early exposure impact on
childhood and adolescence health is more limited [26].
Moreover, socio-economic level has been associated with
the risk of developing CD in some studies, but results
are conflicting [13, 27–32]. For this reason we decided
to control for the possible confounding effect of socio-
economic status by design matching reference individuals
by maternal education. To the best of our knowledge this
has never been done before. We also hypothesised that a
poorer educational and socio-economic condition may
adversely affect health of CD children and adolescents
compared to reference individuals within the same socio-
economic stratum, possibly because of a poorer adherence
to gluten-free diet. However, the analyses stratified by
maternal education showed similar HR of hospital admis-
sion and drug prescription across groups. These results,
although limited by the low number of events particularly
for the hospitalization outcomes and among the most
educated mothers, do not suggest a modifying effect of
maternal education on the association between CD and
healthcare use, but as any novel tested hypothesis they
need to be further replicated in other setting/studies.
Strengths of our study besides the matched design
include the large population size, the longitudinal design
with long follow-up period and the availability of ob-
jective data, with no risk of recall bias. The main limita-
tions are due to the use itself of administrative data with
the inability to directly verify the presence of CD, and
obtain data on compliance with a gluten-free diet. As
regards the identification of CD cases, however, we are
confident that our data are accurate since 71 % of cases
had a biopsy report of villous atrophy, which has been
found to be highly specific (positive predictive value
95 %) for CD in a validation study [33]. Of the remaining
cases, 20 % had a copayment exemption, which in Italy
is based on a physician’s diagnosis. Treatment with a
gluten-free diet may result in decreased consumption of
health care services and drugs, [10] although some studies
suggested that, even after years of compliance with a
gluten-free diet, CD patients have significantly impaired
quality of life [11]. Moreover, we were unable to retrieve
data on outpatient visits and diagnostic procedures, which
would have drawn a more comprehensive picture of
healthcare utilization. A further limitation is that we did
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not exclude from the analyses those subjects already af-
fected by chronic disorders other than CD before the
index date. Therefore, the higher healthcare use we
observed in CD individuals may in part depend on comor-
bidities that were already present before the onset of CD.
Our study should be therefore regarded as exploratory
rather than confirmatory because we did not examine
temporal relationships between CD onset and outcomes.
The aim of this study was to describe healthcare use pat-
tern after CD diagnosis without inferring causal relation-
ships between CD and associated conditions.
Conclusions
Using a population-based birth cohort matched study de-
sign, we showed that young people with diagnosed CD
were at increased risk of later hospitalization and medica-
tion use compared to unaffected peers from the general
population independently from socio-economic status at
birth. Greater healthcare consumption may be explained
both by non-specific health complaints and by complica-
tions and associated conditions of CD. Whatever the mech-
anism, our findings show that the burden associated with
paediatric CD is heavy and persists in the long term, despite
the existence of an effective treatment. Further longitudinal
studies should be devoted to identify factors associated to a
bad prognosis of CD in the paediatric population, in order
to improve the management of this disease.
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